Mabwell Biopharmaceuticals has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration to initiate a Phase IIa clinical study for its anti-ST2 monoclonal antibody, 9MW1911, in patients with moderate-to-severe chronic obstructive pulmonary disease. This regulatory milestone comes on the heels of a completed Phase IIa study in China, where Mabwell reported dose-responsive efficacy signals and a favorable safety profile.
What Mabwell’s 9MW1911 reveals about ST2 as a novel inflammatory target in COPD
The ST2/IL-33 signaling axis is emerging as a promising but largely untapped immunological target in respiratory medicine. In contrast to therapies that focus on bronchodilation or eosinophilic suppression, 9MW1911 is designed to intervene earlier in the inflammatory cascade by blocking IL-33 binding to its ST2 receptor. This approach holds potential for reducing exacerbations in patients whose disease is not driven by eosinophilia and may therefore be less responsive to existing biologics.
Unlike monoclonal antibodies approved for asthma, such as benralizumab or mepolizumab, which rely on blood eosinophil count as a predictive biomarker, 9MW1911 is being positioned as a broader anti-inflammatory agent. This distinction could expand its utility to patients with COPD subtypes that are less well served by current biologics, particularly those with neutrophilic or mixed-cell inflammation. Industry analysts have pointed out that Mabwell may be attempting to redefine the biologics narrative in COPD by bypassing the eosinophil threshold that has limited past development efforts.
Why Phase IIa data from China shifts the clinical risk-reward profile
The Phase IIa trial conducted in China included 100 patients with moderate-to-severe COPD and was structured to assess both safety and early efficacy. Mabwell reported that 9MW1911 was well tolerated across all dose cohorts, with adverse event rates comparable to placebo and no immunogenicity signals detected. More significantly, the company disclosed a dose-dependent reduction in the annualized rate of moderate-to-severe exacerbations, with the recommended Phase IIb dose achieving a greater than 30 percent reduction versus placebo. The reduction in severe exacerbations exceeded 40 percent, and the proportion of patients experiencing such events was substantially lower at 13.3 percent compared to 35 percent in the control arm.
These findings, while encouraging, are not without limitations. The study population was geographically and genetically homogeneous, and the relatively small sample size raises questions about statistical robustness. However, the establishment of an exposure-response model and clear pharmacokinetic trends across dose ranges strengthen the biological plausibility of the observed efficacy. Clinicians tracking respiratory biologics note that these elements form a solid foundation for dose refinement and subsequent regulatory discussions.
What the FDA clearance signals about Mabwell’s global ambitions
Securing United States Food and Drug Administration clearance for a China-originated monoclonal antibody in a mainstream indication such as COPD is a milestone in itself. For Mabwell, it validates the company’s translational pipeline and signals a strategic intent to globalize its portfolio beyond oncology and niche indications. The decision to move directly into a Phase IIa trial in the United States suggests that Mabwell is confident in both its preclinical data package and the translatability of its Chinese clinical results.
This move also puts Mabwell among a new wave of China-based biopharmaceutical companies that are shifting from regional to global development strategies. By targeting an area of high unmet need and clinical complexity like COPD, the firm is demonstrating a willingness to take on regulatory and commercial challenges that larger pharmaceutical companies have approached more cautiously in recent years.
The Phase IIb trial is already underway, with first patient dosing achieved in July 2025 and an interim analysis scheduled after enrollment of at least 120 participants. Mabwell has indicated that it aims to begin a Phase III study by the end of 2026. Regulatory experts suggest that the timing and structure of this next-phase trial will be critical, especially in terms of endpoint definition, duration, and comparator selection. The United States Food and Drug Administration may require robust exacerbation data over a full year and may also request head-to-head comparisons with standard triple therapy regimens to establish value.
Why ST2 targeting in COPD may reshape market expectations
Biologics have historically struggled to gain traction in COPD due to a lack of predictive biomarkers and inconsistent trial outcomes. Most failed to deliver compelling efficacy across diverse patient subtypes, which has kept payers and physicians reliant on inhaled therapies. The introduction of 9MW1911 could change that narrative by offering a broader anti-inflammatory effect that does not depend on eosinophil thresholds.
Mabwell’s approach could be especially attractive in patients who continue to experience frequent exacerbations despite optimized inhaled therapy. These include individuals with recurrent hospitalizations, systemic corticosteroid use, or comorbid conditions that limit steroid tolerance. By targeting the ST2 receptor upstream in the inflammatory cascade, 9MW1911 may offer a new modality for exacerbation prevention that avoids the side effects of chronic steroid exposure.
That said, therapeutic differentiation will hinge on demonstrating additive benefit to existing maintenance therapy. If 9MW1911 is ultimately positioned as an adjunct rather than a replacement, Mabwell will need to address price sensitivity in a cost-conscious respiratory market. Payers may demand hospitalization or steroid-sparing endpoints before authorizing high-cost biologic use, especially in a condition with genericized inhalers and broad therapeutic alternatives.
What regulatory and manufacturing questions remain unresolved
Despite regulatory momentum, several operational risks remain. The ability to scale up manufacturing for a biologic intended for chronic use in a large population will require significant investment in chemistry, manufacturing, and controls infrastructure. Mabwell’s track record in oncology biologics and age-related therapies may not fully translate to the unique supply and distribution demands of respiratory care in Western markets.
In addition, the lack of a validated diagnostic or enrichment strategy for ST2 expression presents a risk in trial design. Without biomarker stratification, Phase III trials may face challenges in patient selection and data variability. Mabwell may need to invest in parallel biomarker discovery or companion diagnostics to support regulatory filings in the United States and Europe.
Furthermore, while the China-based trial met its objectives, the United States Food and Drug Administration may require bridging data or repeat validation in a more demographically diverse population. Differences in exacerbation definitions, reporting practices, and healthcare infrastructure between China and the United States could also impact trial outcomes and their regulatory interpretation.
How Mabwell could position 9MW1911 amid broader industry trends
The pipeline for biologics in respiratory disease has narrowed over the past decade due to repeated setbacks in COPD drug development. With few players currently exploring the IL-33/ST2 axis, Mabwell has a potential first-mover advantage. However, this also means that regulatory precedent is limited and that the company must blaze its own trail in both trial design and commercialization strategy.
If the Phase IIb and Phase III trials validate 9MW1911’s efficacy and safety, Mabwell could emerge as a licensing or acquisition target for multinational pharmaceutical firms seeking to reenter the COPD space with a differentiated asset. Alternatively, the company may explore regional partnerships to support commercialization outside of Asia, particularly if it lacks existing distribution or reimbursement infrastructure in the United States.
Analysts covering biopharmaceutical innovation in China see 9MW1911 as a test case for how domestic firms can break into global mainstream indications through targeted innovation rather than biosimilar competition. The outcome of Mabwell’s clinical program may influence capital allocation decisions across the Chinese biotech sector, particularly for companies contemplating global respiratory or immunology plays.
Why Mabwell’s FDA clearance could mark a turning point for COPD immunotherapy
Mabwell’s advancement of 9MW1911 into Phase IIa trials in the United States represents more than just a regulatory win. It is a bet on a new mechanism of action, a novel market entry strategy, and the growing technical capabilities of China-based biopharmaceutical firms. If successful, 9MW1911 could signal the beginning of a new chapter in COPD care—one defined not by incremental inhaler tweaks, but by biologic interventions capable of altering the course of disease.
However, the burden of proof remains high. With significant clinical, regulatory, and commercial hurdles ahead, Mabwell’s trajectory will depend not only on data but on execution. For now, industry observers will be watching closely as 9MW1911 enters the U.S. clinic, hoping that this anti-ST2 antibody lives up to its mechanistic promise and reopens the door to innovation in a field long marked by therapeutic stagnation.
Mabwell’s anti-ST2 antibody 9MW1911 cleared for U.S. Phase IIa trial: Could this reshape COPD biologics? added by Venkatesh B on
View all posts by Venkatesh B →